RxDoctor Payments DataLook up a doctor →

Steven Davidoff, MD

Critical Care Medicine · Plano, TXNPI 1114956554

Payments from drug & device makers

$364,116in general payments, 2019–2025

Across 967 payments — averaging $376.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$342K
  • Pfizer$7K
  • Sanofi$2K
  • Grifols Shared Services North America, Inc.$2K
  • AstraZeneca$2K
  • Genentech, Inc.$1K
  • plus $9K from 42 others

What the payments were for

  • Consulting fees$5,3631%
  • Speaking & faculty fees$322,53989%
  • Grants$1,0000%
  • Travel & lodging$16,2964%
  • Food & beverage$18,8445%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$364,116 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$169,029
Medicare patients
533
Services billed
1,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter270$203,224
Prolastin CAlpha-1-Proteinase Inhibitor14$123,376
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr161$99,703
Pirfenidone12$51,811
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$38,505
Breo ElliptaFluticasone/Vilanterol78$37,134
Spiriva RespimatTiotropium Bromide48$33,736
EliquisApixaban34$26,352
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$19,707
Arnuity ElliptaFluticasone Furoate59$13,713
Incruse ElliptaUmeclidinium Bromide36$12,010
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$7,529
Qvar RedihalerBeclomethasone Dipropionate16$5,241
Wixela InhubFluticasone Propion/Salmeterol35$2,780
Albuterol Sulfate HfaAlbuterol Sulfate108$2,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$342,245$365,784604 claims
Grifols USA, LLCProlastin C$591$123,37614 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$904$53,44278 claims
AstraZenecaBreztri Aerosphere$1,561$38,50539 claims
PfizerEliquis$7,110$26,35234 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$14$5,24116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →